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Abstract
Childhood onset neurofibromatosis type 2 can be severe and genotype dependent.
We present a retrospective phenotypic analysis of all ascertained children in England
<age 18 (N = 87; male 61%). Mean age at last review was 13.9 years with mean
follow-up 6.5 years. Patients were stratified using a validated score (1A/1B:no NF2
pathogenic_variant in blood; 2A/2B:mild/moderate NF2 constitutional or mosaic
pathogenic_variant in blood; 3: constitutional truncating exon 2-13 pathogenic_variant.
A total of 91% patients had a constitutional NF2 pathogenic_variant (44% de novo).
Mean age at first manifestation was 4.3 and 8.8 years in groups 3 and 2A, respectively.
Bilateral vestibular schwannoma, intracranial meningioma and spinal schwannoma
occurred in 77%, 52% and 65% of group 3 patients, respectively, and 58%, 26% and
33% in 2A. A total of 43% group 3 and 18% 2A had severe unilateral visual loss (logmar
>1.0). Focal cortical dysplasia occurred in 26% group 3 and 4% 2A. A total of 48% of
group 3 underwent ≥1 major intervention (intracranial/spinal surgery/Bevacizumab/
radiotherapy) compared to 35% of 2A; with 23% group 3 undergoing spinal surgery
(schwannoma/ependymoma/meningioma resection) compared to 4% of 2A. Mean age
starting Bevacizumab was 12.7 in group 3 and 14.9 years in 2A. In conclusion, group
3 phenotype manifests earlier with greater tumour load, poorer visual outcomes and
more intervention.
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1 | INTRODUCTION
Neurofibromatosis type 2 (NF2) can be a severe debilitating condition,
particularly if the onset is under the age of 18. It is caused by patho-
genic variants (path_variants) in the NF2 tumour suppressor gene on
chromosome 221 and has a birth incidence of 1 in 25-33000.2 NF2 is
characterised by the development of multiple neurological tumours;
typically bilateral vestibular schwannoma (VS), cranial and spinal
meningioma, other intracranial, spinal and peripheral nerve
schwannoma and spinal ependymoma.3,4 Clinical manifestations can
include hearing and visual loss, peripheral mononeuropathy and cra-
nial nerve palsy.3,5-7 The severity spectrum ranges from incidentally
detected disease in older adults,8 to severe disease presenting in
infancy.9 While adults typically present with VS-related symptoms
such as hearing loss or tinnitus5 children predominantly present with
non-vestibular manifestations related to eye or skin features, or signs
suggesting a cranial nerve palsy (CNP), cranial meningioma or spinal
tumour.7,10-14 Younger age at first manifestation often indicates
increased severity and poorer prognosis and survival.15
While NF2 presenting in later life may cause minor morbidity;
childhood onset NF2 often needs frequent intervention, causes signif-
icant disability, and reduces quality and length of life.3,15-18 Affecting
severity is the nature and extent of the NF2 path_variant.19-22 Most
severely affected are those with constitutional truncating path_-
variants between exons 2-1322-25; in contrast constitutional missense
or splice-site path_variants, or mosaic path_variants cause milder dis-
ease.23,24,26-29 Those affected mildly, although suffering hearing loss,
often live a full lifespan, work and reproduce. Those with severe phe-
notypes, with impaired mobility, vision and hearing, have lower repro-
ductive fitness and less commonly undertake paid employment.30
Management aims to maintain function and slow progres-
sion3,31,32 but is complicated due to fear of radiation induced
malignancy,33 neurosurgical morbidity and Bevacizumab induced
hypertension and proteinuria.34,35 Other agents including Everolimus
have been tried but evidence on efficacy and safety is limited.36 Natu-
ral history NF2 data utilising current management is important, to
inform management options.
Natural history NF2 studies refer to three phenotypes; mild adult-
onset Gardner NF2, severe Wishart pre-pubertal NF2, and the
earliest-onset congenital form.9,32,37 Other studies divided patients
into milder and severe phenotypes according to number of lesions or
age of onset.38 Many studies assess the whole cohort together, mak-
ing extrapolation for individual patients difficult.39-41 The UK-NF2
genetic severity score was devised and validated42 to integrate
molecular data into clinical use and to facilitate collation of genotype
stratified natural history data.
NF2 care in England (population 53.5 million) has been centralised
since 2010 and is co-ordinated through four centres (Cambridge,
London, Oxford and Manchester).43 Care for all children with NF2 in
England is managed through the NF2 service. We have reviewed the
notes of all affected children known to the service. By stratifying phe-
notypic data by genotype the aim is to better understand NF2 natural
history to aid management decisions.
2 | SUBJECTS AND METHODS
All children in England diagnosed with NF2 using the Manchester
criteria5 or with a pathogenic NF2 variant, aged under 18 by April
2016 and cared for through the English NF2 service were included in
the study. NF2 records held within the four NF2 centres were
reviewed primarily by DH, AP and KL, and an anonymised retrospec-
tive data collection proforma completed for each patient.
Patients were stratified using the previously published and vali-
dated UK genetic severity score42(Table 1) and data analysed for
trends. Briefly, 1A/1B represents where no NF2 path_variant was
detected in blood, 2A and 2B represents a mild or moderate, respec-
tively, constitutional or mosaic NF2 path_variant detected in blood
and 3 represents those with a constitutional truncating path_variant
within exons 2-13.
SPSS 23 (Guilford, Surrey, UK) was used for all statistical analyses.
Genetic severity was treated as an ordinal variable. We reported stan-
dard summary statistics throughout with statistical significance of
inferences set to 5%. Directions in trends and associations were hypo-
thesised to reflect an increased clinical severity with genetic severity
score. Trends in demographics, clinical phenotype, interventions, and
MRI features with genetic severity were investigated using Mantel-
Haenszellinear-by-linearχ2 tests of association. Associations between
scalar and ordinal variables, and where necessary controlling for possi-
ble confounders, were investigated using Spearman's correlations, and
where appropriate partial Spearman's correlations, after visually con-
firming monotonic relationships of the variables using scatterplots.
Annual VS growth was calculated for all ears in each genetic severity
group for which scans existed for Bevacizumab-free periods of one or
more years. T tests were used for pairwise comparisons; inspection of
outliers in the pairwise differences revealed they were not extreme
and did not unduly influence the results and they were therefore kept
in the analysis. All statistical comparisons were based on a-priory
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hypotheses and type I error rate was controlled using the Benjamini-
Hochberg procedure.
The study was approved by the National Research Ethics Service
(NRES) Committee-South-West (12/SW/0042) and all procedures
undertaken in the study were in accordance with the 1964 Helsinki
declaration. As there was no active human participation in this study
(as a retrospective, anonymised review of routinely collected clinical
data), no consent was deemed necessary by the NRES committee.
3 | RESULTS
3.1 | Patient demographics
Notes of 87 children (male 53, 61%) were reviewed. Mean age at data
collection was 13.9 years and mean length of follow up 6.5 years.
Table 2 shows the proportions within each genetic severity group
with mean current age, length of follow up, age of diagnosis, age at
first manifestation, the proportion having presymptomatic or diagnos-
tic genetic testing and those with familial (56%) or sporadic (44%) dis-
ease. Presymptomatic testing was more common in group 2A (46%)
and less common with increasing genetic severity (2B 20% and group
3 19%, P = .011). Patients with sporadic disease were more commonly
group 3 (18/38 47%) compared to 2A (6/38 16%); in contrast familial
NF2 patients were more commonly 2A (20/49 41%) than group
3 (13/49 27%; P = .003). Mean age at first manifestation was
4.3 years in group 3 compared to 8.8 years in group 2A (P = .002,
Table 2). Only 12 (41%) familial patients in groups 2B/3 had predictive
genetic testing as NF2 clinical features were already apparent in the
remainder before testing.
3.2 | Molecular profile
No cases were assigned 1A/1B as all cases had an NF2 path_variant
identified in blood (75/87 86% constitutional, 8/87 9% mosaic) or had
familial NF2 with the assumption of a constitutional unidentified NF2
path_variant (4/87 5%, Table 2).
3.3 | Clinical phenotype
3.3.1 | Timing of first manifestation of NF2
In 70% of group 2A, the initial manifestation was VS/other intracranial
lesions on scan, at a mean age of 12.0. In group 3 initial manifestations
were more commonly eye problems (59% at mean age 3.2) including
reduced acuity, squint, cataract or ocular CNP; skin features (21% at
mean age 4.5) and spinal problems (17% at mean age 9.6) with intra-
cranial lesions documented at the time of first manifestations in 28%
TABLE 1 Genetic Severity score
NF2 pathogenic variant detected in blood 2A Mild 2B Moderate 3 Severe
Truncating pathogenic variant
Exon 2-13 constitutional 3
Mosaic 2B
Exon 14-15 Constitutional 2B
mosaic 2A
Exon 1 constitutional/mosaic 2A
Splice site pathogenic variant
Exon 1–7 constitutional 2B
mosaic 2A
Exon 8-15 constitutional 2A
mosaic 2A
Large Deletion excluding promotor or exon 1 constitutional 2B
Large Deletion excluding promotor or exon 1 mosaic 2A
Large Deletion Including promotor or exon 1 constitutional or
mosaic
2A
Small in-frame deletion or duplication constitutional or mosaic 2A
Missense mutation constitutional or mosaic 2A
No NF2 pathogenic variant detected in blood 1A 1B
Meets clinical criteria for NF2 and an identical NF2
pathogenic variant is identified in two separate tumour
samples
1B
Meets clinical criteria for NF2 but analysis of two tumours is
not available to confirm diagnosis
1A
Data in Table 1 are reproduced from Table 1 and Table 2, in Halliday et al.42
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(at mean age 7.8, Table 3). While 11.5% 2A patients were yet to mani-
fest NF2 features at last review (mean age 11 years), only 6.5% group
3 were yet to manifest at mean age 4 years.
3.3.2 | Dermatological features
A significant trend was noted for presence of NF2 skin features
(including NF2 plaques, subcutaneous schwannomas, pigmented and
depigmented lesions) rising from 39% of 2A to 71% of group
3 (Table 4). Features were analysed jointly due to likely under ascer-
tainment in a retrospective review.
3.3.3 | Neurological features
Cranial Nerve Palsy occurred in 26% (Table 4) affecting all three
severity groups. A total of 7/87 (8%) patients had a third CNP; in
one case transient before becoming permanent, and in another case
bilateral. Three cases each had fourth or sixth CNP with 15/87
(17%) having an ocular CNP. Facial palsy occurred in 7/87 (8%) chil-
dren; in two apparent before age 2 and in the remainder noted
after age 11. In two cases (one young onset) a facial nerve
schwannoma/enhancement was seen and in 5 an ipsilateral VS was
noted (size 12-35 mm). A total of 7/87 (8%) cases had involvement
of the lower cranial nerves; with stridor/dysphonia, uni/bilateral
vocal cord palsy, or vagal/hypoglossal nerve palsy. Peripheral
mononeuropathy occurred in 9 cases affecting both upper and
lower limbs; 1/26 2A cases (4%) and 4/30 (14.3%) and 4/31
(12.9%) 2B and 3 cases, respectively. Two cases had finger weak-
ness, one had ulnar distribution wasting, one had arm wasting from
a brachial plexus lesion, one had unilateral weakness of foot dors-
iflexion, two had quadriceps wasting (one from an L3/4 lesion), one
had long standing unilateral arm and leg weakness.
A significant association was seen with severity and proportion
having one or more seizures (P = .03, Table 4). Mean age of first
TABLE 2 Cohort characteristics: demographic and molecular data
2A Mild 2B Moderate 3 Severe Overall
N = 26 (29.9%) N = 30 (34.5%) N = 31 (35.6%) N = 87 (100%)
N Column % N Column % N Column % N Column %
Pathogenic variant:*
Familial 20 77% 16 53% 13 42% 49 56%
Sporadic 6 23% 14 47% 18 58% 38 44%
Type of genetic test:*
Presymptomatic 12 46% 6 20% 6 19% 24 28%
Diagnostic 14 54% 24 80% 25 81% 63 72%
Mean SD Mean SD Mean SD Mean SD
Years of follow-up 6.0 4.5 7.1 4.8 6.2 3.9 6.5 4.4
Age of confirmed NF2 Diagnosis 8.0 5.3 7.9 5.4 6.7 5.2 7.5 5.3
Age at presymptomatic test 8.5 5.5 5.4 5.5 3.4 4.9 6.2 5.6
Age at diagnostic test 7.6 5.3 9.5 4.8 7.6 5.0 8.2 5.0
Age of first manifestation* 8.8 6.1 7.3 4.5 4.3 3.8 6.6 5.1
Age at last review 14.0 4.6 15.0 3.5 12.9 4.6 13.9 4.3
Pathogenic variant
Mosaic in blood 3 12% 5 16% 8 9%
Constitutional variants
Nonsense 0 0% 0 0% 14 45% 14 16%
Frameshift 2 8% 3 10% 17 55% 22 25%
Splicing 4 15% 17 68% — — 21 24%
Large deletion 6 23% 5 17% — — 11 13%
Missense 5 19% — — — — 5 6%
Small in-frame deletion 0 0% — — — — 0 0%
Chromosomal deletion 2 8% — — — — 2 2%
Familial NF2 (no NF2 mutation) 4 15% — — — — 4 5%
Total constitutional 23 88% 25 84% 31 100% 79 91%
*P < .05.
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TABLE 3 First manifestations of NF2 related to genetic severity group, detailing NF2 related features that were documented, or detected on
imaging, at the time of first clinical assessment
2A Mild 2B Moderate 3 Severe Overall
No manifestation at
last reviewba
N (% of total column) 3 11.5% 4 13.3% 2 6.5% 9 10.3%
Age at last review (M, SD) 11.0 7.8 15.0 1.8 4.0a .0 11.2 6.1
First manifestation: Multiple manifestations per patient possible, N = 78
Eye problems N, column % 5 22% 14 54% 17 59% 36 46%
Age at manifestation (M, SD) 1.4 2.6 7.0 4.9 3.2 3.1 4.4 4.3
Skin problems N, column % 2 9% 5 19% 6 21% 13 17%
Age (Mean, SD) 14.0 5.7 7.8 3.4 4.5 3.2 7.2 4.7
Head lesions, of which: N, column % 16 70% 11 42% 8 28% 35 45%
Age (Mean, SD) 12.0 4.0 10.4 3.6 7.8 4.8 10.5 4.3
—VS N, column % 12 52% 8 31% 5 17% 25 32%
Age (Mean, SD) 13.1 3.0 11.1 3.2 9.4 4.9 11.7 3.6
—meningioma N, column % 1 4% 6 23% 1 3% 8 10%
Age (Mean, SD) 2.0 — 9.2 4.4 10.0 — 8.4 4.5
—other head lesion N, column % 2 9% 5 19% 2 7% 9 12%
Age (Mean, SD) 10.5 .7 12.0 2.0 3.0 1.4 9.7 4.1
Spinal lesions N, column % 1 4% 2 8% 5 17% 8 10%
Age (Mean, SD) 18.0 — 7.0 1.4 9.6 3.0 10.0 4.2
Motor function problems N, column % 3 12% 2 8% 4 14% 9 10%
Age (Mean, SD) 8.0 8.0 4.0 2.8 6.3 4.6 6.1 4.8
Neuropathy N, column % 0 0% 1 4% 1 3% 2 3%
Age (Mean, SD) — — 10.0 — 14.0 — 12.0 2.8
Cranial nerve palsy N, column % 0 0% 1 4% 1 3% 2 3%
Age (Mean, SD) — — 6.8 4.6 2.0 1.4 6.4 5.2
Raised intracranial
pressure
N, column % 0 0% 1 4% 2 7% 3 4%
Age (Mean, SD) — — 15.0 — 5.5 4.9 8.7 6.5
Developmental delay N, column % 2 9% 0 0% 0 0% 2 3%
Age (Mean, SD) 1.5 .7 — — — — 1.5 .7
Hearing problems N, column % 1 4% 0 0% 1 3% 2 3%
Age (Mean, SD) 14.0 — — — 5.0 — 9.5 6.4
Epilepsy/seizures N, column % 0 0% 2 8% 0 0% 2 3%
Age (Mean, SD) — — 2.0 1.4 — — 2.0 1.4
Cortical dysplasia N, column % 0 0% 1 4% 1 3% 2 3%
Age (Mean, SD) — — 3.0 — 10.0 — 6.5 4.9
Pes cavus N, column % 0 0% 1 4% 0 0% 1 1%
Age (Mean, SD) — — 10.0 — — — 10.0 —
For children diagnosed through predictive genetic testing this may have been first NF2 features noted on routine surveillance imaging. For children
presenting symptomatically, the table includes all features clinically documented or identified on scan at the time of the initial presentation.
at(28) = 12.56, P < .001, the severe patients who have not manifested were significantly younger at last review compared to severe patients who have
manifested (M = 13.5, SD = 4.1).
bEye problems specified included: visual impairment or loss, squint, optic nerve hypoplasia and blindness, cataracts, retinal hamartoma, amblyopia, field
defect, ptosis, 3rd nerve palsy. Skin problems specified included: NF2 plaques, pigmented or depigmented patches and subcutaneous schwannomas. Other
head problems specified included: Non-vestibular intracranial schwannoma (N = 5), gingival lump (N = 1), pharynx schwannoma (N = 1), low grade
glioma/hamartoma (N = 1), cochlear nerve schwannoma (N = 1). Spinal lesions specified included: spinal ependymoma (N = 1), spinal meningioma (N = 2)
and spinal schwannoma (N = 6), extradural schwannoma (N = 1), spinal lesion (unspecified, N = 1). Motor function problems specified included:
abnormalities with gait (N = 5), weakness (N = 1), foot drop (N = 1), leg wasting (N = 1), upper motor neuron (N = 1). Developmental delay included
2 severe/global developmental delay cases: 1 secondary to chromosome 22 microdeletion and 1 ring chromosome 22.
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seizure was 7.1 years (range 3-11). One 2B case had a single sei-
zure aged 1 with normal brain MRI, whereas the second had epi-
lepsy between ages 3-16 and focal cortical dysplasia on MRI. The
group 3 patients included: one with initially nocturnal, later includ-
ing daytime seizures from age 6 to 12, with MRIs showing focal
cortical dysplasia aged 8 and meningioma age 14; one patient
with complex partial seizures from age 8, who had an arachnoid
cyst, focal cortical dysplasia and subcortical signal change; one
patient with seizures from age 8, who had an area of men-
ingioangiomatosis, cortical dysplasia and cerebellar cortical dysplasia
and prominent perivascular spaces; one patient who had seizures
aged 11-13, which resolved after removal of an area of men-
ingioangiomatosis/cortical dysplasia; one patient with a pilocytic
astrocytoma, who had a seizure age 11; and one patient with a cho-
roid plexus cyst and temporal lobe cortical dysplasia, who had a sin-
gle seizure age 9.
3.3.4 | Hearing
In all three groups a non-statistically-significant decline was seen in
hearing from diagnosis to last assessment (Table 4) with 91% having
bilateral normal hearing at presentation to 83% at last review. Two
young children (group 3) lost hearing unilaterally: age 4 from a
cochlear nerve schwannoma and age 5 from a VS. Nine children in
total had severe or total hearing loss, unilateral in 8 and bilateral in
one. There was no correlation with genetic severity. Three children
had a hearing implant: cochlear (ages 14 and 17) and auditory
brainstem (age 11).
3.3.5 | Visual acuity
Thirty per cent of children had severe visual impairment (logmar >1.0)
in one eye, with proportions significantly increasing with genetic
TABLE 4 Clinical phenotype of NF2
2A Mild 2B Moderate 3 Severe Overall
N = 26 (29.9%) N = 30 (34.5%) N = 31 (35.6%) N = 87 (100%)
N Column % N Column % N Column % N Column %
NF2 skin features (N = 75)* 7 39% 18 62% 20 71% 45 60%
Neurological features
Seizures* (N = 84) 0 0% 2 7% 6 19% 8 9%
Cranial nerve palsy 5 19% 10 33% 8 26% 23 26%
III, IV, VI 4 15% 6 20% 5 16% 15 17%
VII 0 0% 4 13% 3 10% 7 8%
IX, X,XII 1 4% 5 17% 1 3% 7 8%
Mononeuropathy (N = 84) 1 4% 4 13% 4 13% 9 10%
Focal amyotrophy (N = 84) 0 0% 4 13% 1 3% 5 6%
Hearing loss
Bilateral normal hearing at diagnosis 22 85% 29 97% 28 90% 79 91%
Bilateral normal hearing at last review 20 77% 27 90% 25 81% 72 83%
Severe/total hearing loss in 1 ear 3 8% 2 7% 4 6% 9 2%
Hearing implant 1 4% 1 3% 1 3% 3%
Visual features
Any eye feature binarya 9 34.6% 21 70.0% 23 74.2% 53 61%
logMar>1.0 in worse eye (N = 69)* 3 18% 6 25% 12 43% 21 30%
logMar>0.3 in better eye(N = 70) 3 16% 4 17% 9 32% 16 23%
logMar>1.0 in better eye (N = 71) 1 5% 2 8% 0 0% 3 4%
Cognitive, Behavioural and Psychological manifestations
Developmental delayb 3 12% 1 4% 0 0% 4 4.7%
Attention deficit hyperactivity disorder 1 4% 0 0% 2 7% 3 3.5%
Autism Spectrum Disorder 1 4% 0 0% 2 6% 3 3.5%
Psychological issues 8 32% 6 21% 10 33% 24 29%
Table detailing NF2 features related to genetic severity group that were noted clinically or present on imaging at last review.
*P < .05.
aOne or more eyes with any or the following features: lens opacity, epiretinal membrane, retinal hamartoma, amblyopia, squint/ocular mobility, diplopia,
nystagmus, ptosis, optic nerve sheath meningioma, optic atrophy, papilledema, CN III tumour.
bDevelopmental delay secondary to chromosome 22 microdeletion (N = 2) and ring chromosome 22 (N = 1). Mild delay noted in one child with small
intragenic deletion.
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severity (Table 4; P = .024). Twenty-three per cent had mild visual
impairment in their better seeing eye. Of group 3 patients 12 (43%)
had severely affected vision in one eye, and 9 (32%) had impaired
vision (LogMar 0.3 or greater) in their better seeing eye. Contributing
to the visual loss included retinal hamartoma (N = 10), cataract (N = 4),
epiretinal membrane (N = 3), optic nerve sheath meningioma (N = 3),
suprasellar meningioma (N = 1), an optic pathway lesion (N = 1), and
optic atrophy from prolonged raised intracranial pressure associated
with an undiagnosed intracranial meningioma (N = 1). Overall 61% of
all children had at least one NF2 eye feature with proportions rising
significantly with genetic severity (P = .001).
3.3.6 | Cognitive and behavioural difficulties
Diagnosis of attention-deficit-hyperactivity-disorder(ADHD) and
autistic-spectrum traits had been noted in a small proportion (3.5%
TABLE 5 Table detailing ages and numbers of key NF2 features, and tumour burden on MRI at last review, according to genetic severity
(cranial MRI N = 79, spinal MRI N = 71)
Tumour load
2A 2B 3 Overall
Mild Moderate Severe
Age when: Mean SD Mean SD Mean SD Mean SD
First head MRI* 11.5 3.5 11.2 4.0 9.8 3.3 10.8 3.7
First VSa detected* 12.5 3.1 12.3 3.0 10.0 3.3 11.5 3.3
Bilateral VS* 12.5 3.1 12.1 3.8 10.2 3.3 11.5 3.6
First VS >1CM 13.6 2.7 13.8 1.9 12.3 3.1 13.1 2.7
VS growth rate (cm/year) .15 .14 .18 .23 .21 .31 .18 .23
Number of patients and % within genetic severity N Column % N Column % N Column % N Column %
VS > 1 cm at first scan 4 19% 9 39% 9 33% 22 31%
No VS* 7 27% 8 27% 6 19% 21 24%
Unilateral VS* 4 15% 0 0% 1 3% 5 6%
Bilateral VS* 15 58% 22 73% 24 77% 61 70%
Intracranial meningioma* 6 26% 11 38% 14 52% 31 38%
Non vestibular cranial schwannoma* 8 35% 17 59% 23 85% 48 61%
Spinal ependymoma* 4 19% 12 50% 11 42% 27 38%
Spinal schwannoma* 7 33% 16 67% 17 65% 40 56%
Spinal meningioma 2 10% 6 25% 5 19% 13 18%
Extradural schwannoma* 1 5% 11 46% 8 31% 20 28%
Extraspinal schwannoma* 0 0% 3 13% 6 23% 9 13%
Atypical MRI anomaly
Number of patients with MRI anomalies* 5 22% 8 28% 17 63% 30 38%
Focal cortical dysplasia* 1 4% 4 14% 7 26% 12 15%
Cerebellar cortical dysplasia* 1 4% 2 7% 6 22% 9 11%
Brain stem or cerebellar peduncle lacunar infarcts 1 4% 1 3% 1 4% 3 4%
Abnormal choroid plexus cyst/calcification 0 0% 0 0% 2 7% 2 3%
Meningioangiomatosis 0 0% 0 0% 2 7% 2 3%
White matter hyperintensity 0 0% 1 3% 1 4% 2 3%
Prominent perivascular spaces 0 0% 1 3% 1 4% 2 3%
Chiari I malformation 0 0% 1 3% 0 0% 1 1%
Pilocytic astrocytoma of optic pathway 0 0% 0 0% 1 4% 1 1%
Frontal lobe ependymoma 1 4% 0 0% 0 0% 1 1%
Developmental venous anomaly 0 0% 1 3% 0 0% 1 1%
Cystic encephalomalacia 0 0% 0 0% 1 4% 1 1%
Cortical malformation 0 0% 0 0% 1 4% 1 1%
*P < .05.
aVestibular schwannoma.
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each), in keeping with population limits, however specific
neurocognitive assessments were not available to confirm these diag-
noses. Developmental delay was noted in 4.7% (Table 4), in 2A being
attributed to chromosomal disorders: Ring Chromosome 22 associated
with severe global delay; and chromosome 22 microdeletions exten-
ding beyond the NF2 gene associated with variable delay and/or
autistic-spectrum features One 2B child with a small intragenic NF2
deletion had mild delay reported.
In contrast, 24 patients (29%) had psychological issues, mostly
related to low mood and anxiety. There was no relation between psy-
chological issues and genetic severity.
3.3.7 | Atypical features
Atypical features were more common in group 3. Vascular anomalies
in group 3 included one patient each with coarctation of the aorta,
renal artery stenosis and a pontine infarct presenting with upper
motor neurone signs age 14. A second child, with a 22q microdeletion
including NF2 (2A), developed a pontine stroke secondary to vertebral
artery stenosis. One child (2B) had delayed growth aged 15 and one
(3) had constitutional delay of growth and puberty. Unusual eye fea-
tures included one each of morning glory anomaly (3), microtropia (3),
and optic nerve hypoplasia causing unilateral blindness (2A). One child
each had removal of a pilomatrixoma (2A) and exostosis (2B). One
child (with 22qdeletion) had sub-glotic stenosis and laryngomalacia
(2A), and three had developmental delay secondary to chromosomal
deletions (2A). One child had pan-hypopituitarism associated with
hypothalamic, suprachiasmal meningioangiomatosis (3).
3.3.8 | Tumour burden
Reports of cranial and spinal MRI were available in 79 and 71 patients
(Table 5). Table 5 illustrates the tumour load according to severity
groups. Features seen on first MRI scan for group 3 children are given
in Supplementary Table S1. There were significant trends across
severity for tumour load (P < .051). VS size greater than 1 cm at first
scan was present in 19% of 2A and 31% of the whole cohort, and not
related to genetic severity. These patients were significantly older at
first scan compared to those with smaller VS(t(69) = 5.25,P < .001).
There was little difference in the rate of growth of VS across severity
groups (Table 5, P = .89).
3.3.9 | Atypical MRI features
Thirty-eight per cent of the cohort (Table 5) had an atypical MRI anom-
aly, with a significant trend with genetic severity (P = .002). Most fre-
quently seen were focal cortical dysplasia in 12 (15%) patients (frontal
lobe N = 4, parietal lobe N = 3, temporal lobe N = 1, area not specified
N = 4) and cerebellar cortical dysplasia in 9 (11%), the prevalence of
which increased with genetic severity (P = .017, P = .024, respectively).
3.4 | Paediatric NF2 management
3.4.1 | Interventions
Fifty-eight major interventions (VS surgery/spinal surgery/non-VS
intracranial surgery/radiotherapy/bevacizumab) were performed
along with 20 other treatments (Table 6). Thirty-five per cent of 2A
patients underwent ≥1 major interventions, compared to 48% in
group 3. In the whole cohort 37 patients (42%) had ≥1 and 14 (16%)
≥2 major interventions, increasing to 44 (50%) and 22 (25%), respec-
tively when including all procedures. Most frequent intervention was
bevacizumab (26%). Only 5 (6%) children underwent VS surgery com-
pared to 14 (16%) each undergoing spinal surgery or non-VS intracra-
nial surgery.
3.4.2 | Bevacizumab
Bevacizumab was given to 23 children (26%) with four centre
approval, starting at a mean age of 14.9 years in 2A and 12.7 years in
group 3 (P = .008). The indication was for rapidly growing unilateral
vestibular schwannoma (UVS) in 18 and bilateral vestibular
schwannoma (BVS) in 3 cases, and one each for a lumbosacral
schwannoma and a cystic spinal ependymoma. In two cases surgery
occurred later on the target VS.
3.4.3 | Intracranial surgery
5 (6%) children underwent VS surgery. In two cases at a young age
(8 and 11), both pre 2011, before routine use of bevacizumab. Both
were later given bevacizumab for growing VS; in one case after
6 years (for bilateral growth), and in the second case 1 year post-
surgery (for a growing contralateral tumour). Three children had VS
surgery more recently, aged 14, 15 and 18. All three also took
bevacizumab; one three years post-surgery (for a growing contralat-
eral VS), two for growing VS prior to surgery (treatment for 1 year
before surgery to the same lesion age 15, and in the second case for
3 years for growing BVS, before unilateral VS surgery aged 18).
A total of 14 (16%) patients had non-VS intracranial surgery occur-
ring in all three groups. Four surgeries (mean age 4.8 years), occurred
pre-2010: for optic nerve sheath meningioma; to debulk a hypotha-
lamic supra-chiasmal mass; to resect a symptomatic posterior fossa
meningioma; and an exploratory craniotomy for a pericavernous
meningioma later treated with radiotherapy. Ten surgeries occurred
after 2010 (mean age 12.2 years). In 8 of these, surgery was to resect
a meningioma (grade II in 5/7 cases where histology was available);
one patient had resection of a grade II frontal lobe ependymoma aged
15; and one had decompression of the optic nerves. In 5/14 cases
(36%) the surgery occurred at or before diagnosis of NF2 and in
12/14 (86%) cases the indication was symptoms, growth, position or
size of the lesion. In three cases the indication was threat to vision
(optic nerve meningioma surgery, optic nerve decompression, or re-
section of suprasellar meningioma encasing the optic nerve).
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3.4.4 | Spinal surgery
Other than 2 surgeries pre-2010, all occurred after the National NF2
service was established. Five were for ependymoma (mean age
11.6 years), 3 for grade 1 meningioma (mean age12.3 years) and 6 for
schwannoma (mean age 10.2 years). Of the 3 ependymoma cases
where histology was available all were grade II. In 7/14 (50%) surgery
occurred at or before the diagnosis of NF2, due to the child pre-
senting symptomatically from the spinal lesion (or in one case symp-
tomatic from a synchronous intracranial lesion). In 10/12 post-2010
cases there was clear documentation of symptoms or signs arising
from the lesion, or significant growth as the indication for surgery.
3.4.5 | Radiotherapy
Two 2B children underwent radiotherapy; one, aged 8, for a large
bilateral optic nerve sheath meningioma severely threatening vision;
and one proton beam therapy aged 15, for an intracranial meningioma
inaccessible to surgery. No child had radiotherapy for VS.
TABLE 6 Interventions
2A Mild 2B Moderate 3 Severe Overall
Age at intervention: Mean SD Mean SD Mean SD Mean SD
First major intervention 11.9 4.4 11.5 3.7 10.4 3.5 11.1 3.8
Bevacizumab* 14.9 1.3 11.8 6.3 12.7 2 12.9 4.2
Non VS intracranial surgery 10.2 5.5 10.6 4.0 9.3 5.9 10.1 4.8
Spinal surgery 4 11.3 4.9 10.7 3.5 10.5 4.3
Other treatments 14.3 0.6 12 5.7 9.1 6.8 11.3 5.8
Proportion of patients having an intervention N % N % N % N %
VS surgerya 1 4% 3 10% 1 3% 5 6%
Radiotherapy 0 0% 2 7% 0 0% 2 2%
Spinal surgeryb 1 4% 6 20% 7 23% 14 16%
Non-VS intracranial surgery 5 19% 5 17% 4 13% 14 16%
Bevacizumab 6 23% 8 27% 9 29% 23 26%
Other treatments: 3 12% 9 30% 8 26% 20 23%
Eye procedures (squint surgery, lid weight, patching, resection of orbital schwannoma) 9 10%
Resection of peripheral schwannomas (brachial plexus, finger, foot) 3 3%
Orthopaedic surgery (spinal fixation, epiphyodesis of knee, Achilles tendon surgery 3 3%
Insertion of shunt 2 2%
Vocal cord procedures 2 2%
Insertion of cochlear implant 1 1%
Vascular surgery (renal and aorta) 2 2%
Other 2 2%
By number of major interventions:
0 17 65% 17 57% 16 52% 50 57%
1 6 23% 7 23% 10 32% 23 26%
2 or more 3 12% 6 20% 5 16% 14 16%
By total number of interventions:
0 16 62% 13 43% 14 45% 43 49%
1 7 27% 7 23% 8 26% 22 25%
2 or more 3 12% 10 33% 9 29% 22 25%
*P < .05.
a5 Vestibular schwannoma S surgeries: 2 partial retrosigmoid (1 cochlear nerve preserving), 3 translabyrinth (of which: 2 were partial; 1 was cochlear nerve
preserving).
bSpinal surgery included 2A:schwannoma (N = 1); 2B ependymoma (N = 2), meningioma (N = 1), schwannoma (N = 3); group 3 ependymoma (N = 3),
meningioma (N = 2), schwannoma (N = 2).
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4 | DISCUSSION
To raise paediatric awareness of NF2, we previously reported in detail
the presenting features of the sporadic patients.14 Including here all
87 children with NF2 in England, we present the largest series of pae-
diatric NF2, and the first stratified by genetic severity. As the aim of
the paper was to report phenotype related to severity grouping we
have pooled data from both symptomatic and presymptomatic chil-
dren known to have NF2. Several previous series have reported under
25 patients.7,10,12,13,39 Evans et al reported 68 English patients aged
under 16 in 1999 precluding overlap with this cohort.11 Other than
children as yet undiagnosed, this study represents almost complete
ascertainment of paediatric NF2 in England and reflects current
management.
The data reveal that paediatric NF2 is overwhelmingly (91%) con-
stitutional; in contrast to all-age cohorts where 33%-58% have likely
mosaic disease.42,44 No patients were assigned group 1 (sporadic with
no NF2 path_variant identified in blood), as these patients typically
present at older ages.42 Previous guidelines recommended predictive
genetic testing aged 10 in children at 50% risk for NF2, with MRI sur-
veillance starting aged 10-12.3,45 Only 24/49 (49%) patients with
familial NF2 had a predictive genetic test, as in the remainder, NF2
features were noted before genetic testing. This data shows that for
group 2B and 3 patients to have predictive testing, this would need to
occur much younger than age 10, due to the early age at first manifes-
tations. As 33% of group 3 patients had a VS > 1 cm on first scan, a
feature strongly associated with later age at first scan; the recommen-
dation for first scan age 10 is validated, and reaffirms the importance
of timely diagnosis.14
This study illustrates the major physical and psychological impact
of paediatric NF2. Although a clear trend in tumour load and interven-
tion was apparent with severity, all groups had a significant burden of
disease with need for major intervention. The significant trend in pro-
portion with VS and other neuroaxis lesions illustrates that genotype-
phenotype differences emerge from childhood, with more severe
manifestations in group 3 compared to group 2A patients.
One or more seizure occurred in 19% of group 3 and 9% of the
whole cohort, comparable to previous studies5 where in 6/7 cases sei-
zure was linked to meningioma/VS.11 In our cohort 12 patients had
cortical dysplasia of which 6 (46%) had one or more seizure. While dif-
ficult to attribute the cause of the seizure(s) an apparent association
with cortical dysplasia was seen in 6/8 cases (75%). EEG recordings
were unfortunately not available, but for future analyses would be
helpful to delineate any causative effect of the cortical dysplasia on
seizure development. Spinal lesions were more prevalent in 2B/3
patients compared to 2A, as noted previously where 17/28 (61%)
patients with spinal ependymoma had truncating path_variants in
exons 2-13.4
MRI anomalies were predominantly seen in group 3 patients, nota-
bly focal cortical dysplasia and cerebellar cortical dysplasia. The clinical
significance of these features is uncertain but may suggest a role for
Merlin in brain development. Vascular anomalies were seen both
intracranially, previously described in detail46 and in major vessels,
and three patients had features suggestive of brainstem or cerebellar
peduncle lacunar infarcts, further suggesting that vascular abnormality
is a feature of NF2.
This study highlights the significant threat to vision in children also
at high risk for bilateral deafness. A previous study found that 14% of
childhood-onset NF2, retained visual acuity of 1.0 (equivalent to
logMar 0.0) in both eyes after 12 years follow up.6 We found that
43% of group 3 patients had severely affected vision in one eye
within childhood. We have previously reported correlation of NF2
specific eye features with genetic severity.47 As this was a retrospec-
tive review of clinical records it was not possible to ascertain to what
extent each individual ophthalmic feature contributed to visual impair-
ment, however contributing to the visual loss in our patients were
both tumour related lesions such as optic nerve sheath meningioma,
along with cataract, retinal hamartoma and epiretinal membrane.
Given the eventual threat of multisensory impairment in these chil-
dren, and the high proportion with visual problems in childhood, 1-2
yearly ophthalmic review from infancy/diagnosis is needed in 2B/3
children to minimise preventable loss of vision.
While it is unusual for NF2 related hearing loss to occur in young
children, two children developed unilateral deafness very young from
cochlear or VS. In a recent all age NF2 cohort 50% of severe patients
were predicted to lose hearing by 32 years.48 In the current cohort
only 83% retained bilateral normal hearing at the time of the last
review. This data demonstrates that exceptionally, loss of hearing in
the first ear can occur from a very young age.
Most frequent interventions were bevacizumab, non-VS intracranial
surgery and spinal surgery. While meningioma in NF2 is more
commonly grade I, of the 10 post-2010 cases of non-VS intracranial
surgery, this was for grade II lesions in the 6/8 with available histol-
ogy. Furthermore resection of a grade II frontal ependymoma is atypi-
cal, as NF2 ependymoma is typically spinal.49 Of the spinal surgery
occurring post-2010 in 6/12 (50%) it occurred before NF2 specialist
review, mostly for symptoms or neurological signs. In 5 cases surgery
was to resect spinal ependymoma. Frequently NF2 related
ependymoma are observed and may not need resection. Ideally if the
diagnosis of NF2 is apparent at presentation, unless urgent surgery is
needed, rapid referral and assessment by a specialist NF2 MDT prior
to surgery may limit avoidable intervention.
VS surgery only occurred three times post-2010, with preference
for bevacizumab in rapidly growing VS. The mean rate of VS growth
did not vary with genetic severity, in keeping with previous studies.50
It is therefore likely that the possible dominant negative effect of
truncating variants acts only as a driver for tumour development and
that complete loss of NF2 function occurs similarly across different
genetic variants in the developed tumour thus showing no difference
in growth rates. In England bevacizumab has strict eligibility criteria of
4 mm growth in 12 months. Group 3 patients commenced treatment
younger than 2A patients, indicating either that rapid VS growth
occurred at a younger age in group 3, or a greater willingness to start
bevacizumab younger in group 3 patients, with likely more severe
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disease. Use of bevacizumab did not always avoid surgery (2/21 cases
had later VS resection) but likely deferred surgery in some cases.
The main limitation of this study is that as a retrospective review
of routinely collected data, we were dependent on clinical record
keeping, rather than utilising prospectively gathered data. A full data
set was not possible for all cases such as visual acuity at presentation
and last review, so we were unable to document visual loss over time.
The main limitation for a natural history study is the mean follow up
length of 6.5 years and mean age at last review of 13.9 years, meaning
that many key outcomes such as hearing would not have been signifi-
cantly affected by last review. Following this cohort prospectively, will
allow us to develop a longer term dataset of NF2 natural history in
these patients.
Managing NF2 is complex. This study highlights some key areas
for surveillance, in addition to routine hearing and MRI. With 43%
group 3 having essentially lost vision in one eye; early and frequent
eye review is important to limit preventable loss of vision. With 29%
reporting anxiety and low mood, psychological support is essential for
children with NF2 to improve outcome. As 8% had a lower CNP, with
unilateral or bilateral vocal cord or bulbar palsy, it is helpful to regu-
larly review speech and swallow in the 2B/3 patients.
The NF2 genetic severity score allows documentation of the dif-
fering phenotypes emerging from childhood. While patients with
familial NF2 will have an expectation of likely severity, those with
sporadic NF2 do not have this reference point. A severity score based
on genotype can in part suggest the likely future phenotype. We have
collected detailed phenotypic information from all children known to
have NF2 within England managed using current protocols; by further
developing genotype derived natural history data the aim is that we
can better inform clinicians and patients to aid NF2 management.
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